ClinicalTrials.gov
public full text
Public Domain
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)#911883
- A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma#1137980
- Clinical and pathological characteristics of thin cutaneous melanomas with rapid recurrence#157798
- Clinical and pathological characteristics of thin cutaneous melanomas with rapid recurrence.#154947
- High response rate to PD-1 blockade in desmoplastic melanomas#614659
Record · ID 1124510
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive